This article is more than 5 years old. Information may no longer be current.
Study identifies cutoff values for minimum clinically important improvement on BASDI, BASFI for AS
Click Here to Manage Email Alerts
As results showed a significant variation in patient-acceptable symptom state and minimum clinically important improvement values depending on disease duration and baseline disease activity in patients with ankylosing spondylitis, researchers suggested a cutoff of 1.1 for the Bath Ankylosing Spondylitis Disease Activity Index and 0.6 for the Bath Ankylosing Spondylitis Functional Index.
Researchers tested the consistency of the minimum clinically important improvement (MCII) and the patient-acceptable symptom state (PASS) according to human leukocyte antigen-B27 status, presence or absence of spondyloarthropathy extra-articular manifestations, age, sex, disease duration and baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) in 283 patients (76% were men) with ankylosing spondylitis. After 4 weeks, researchers defined PASS by asking patients if they considered their condition of ankylosing spondylitis during the past 48 hours as acceptable forever. MCII was defined as patients reporting moderate or slightly important improvement.
In the BASDAI, results showed an overall cutoff of 4.1 for PASS and of 0.7 for MCII. For the BASDI, PASS had an overall cutoff of 3.8 and MCII had an overall cutoff of 0.4. According to subgroup analysis, PASS and MCII were significantly associated with disease duration and baseline BASDAI/BASFI. Researchers noted MCII was 1.1 for the BASDAI and 0.6 for the BASFI among patients with active disease. – by Casey Tingle
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts